about
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicityPhase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.Intrathecal liposomal cytarabine: more friend than foe?Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia.A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.A revised definition for cure of childhood acute lymphoblastic leukemia.A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhoImpact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphomaSpinal epidural lipomatosis in children with hematologic malignancies.Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies.NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cellsThrombophilia in childhood.Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcomeETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.Potential of gene expression profiling in the management of childhood acute lymphoblastic leukemia.Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia.Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza.Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemiaIndividualized therapy for childhood acute lymphoblastic leukemiaThe Impact of Persistent Leukoencephalopathy on Brain White Matter Microstructure in Long-Term Survivors of Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacyInotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaCorrection: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
P50
Q28115755-2C574EB1-77DD-42B5-8482-DD7E29CB98DEQ33437770-A57A1428-B5BC-486C-BD53-D20967C27A99Q33577149-2E4E24D7-1E8A-4E61-A823-30B09F9A024FQ33645862-BF7B1832-5C03-4BE8-B39B-E900E1EA07DAQ33680280-674FDC88-FF66-47F0-A5C2-F749ADB00BB7Q33688248-1A28CEB6-FAD0-4341-AD7C-9D65BA1FF42BQ34138276-E41D0BAB-B8D8-4BFC-85B5-4CF55C9DAC46Q34267235-B0CE8A78-8CCA-4C7B-98ED-24629B420322Q34369388-830FA6E4-DF62-4404-9171-FB3E69C4FFF0Q34429332-2BCF9D4C-FDD8-4125-B417-AB6DE794A21CQ34547528-E675F36E-F3D9-4737-AC95-9D278EB16790Q34598903-BBE648C1-22F2-4E55-B1F2-C25D818E5457Q34679298-374F54A9-50FF-425F-89EB-4DFFF7EE3C2AQ35065477-2AC3C6BB-C9F7-4C3A-81D4-E4CC7FEA25BBQ35152064-BDEFCD2E-2014-4651-8DE5-1E61EF20D25EQ35202329-8163087A-0FBF-40C6-96AE-01CC4C09B18CQ35605949-460D6676-0C69-48B1-9A1C-FA849CBDC1BBQ35665990-53D54C3C-01DB-41CC-8D9B-0230DF7F3235Q35765508-3805463E-E669-4913-86F2-46B315B22010Q35876592-B5F938BB-583D-40AD-9266-2C8EC3AD16D7Q35936879-85D0CE6E-EBE8-4BA2-820F-A0D62645B224Q36182008-1D321D71-92AA-41A0-8979-15C76EF09AFEQ36831044-80E86BF0-3FD0-4836-A754-6E34082A413DQ37331114-09D73F92-AA52-43F8-9488-2C7F3033EDDDQ37389632-B3A27FF4-91BE-4C0F-BE1D-26AB2AAD4122Q37627699-B5CDA1C6-DF8B-4DC3-A2EC-0B58BFE6C036Q37720291-743584F8-018A-47B9-A5D8-3237AA0A81EFQ39361130-DDB72CCB-E1B6-4E5D-BA7E-A01E505556F7Q39760392-40DC33D3-1DF3-4126-BF76-A6F358C840A9Q42324924-12F1274F-6F1F-41FD-9126-A412D56321E0Q43209041-DFF05559-58CB-435E-B385-288C56A8FDACQ46771812-0A8D1ED7-7BEA-4B3A-8442-CF142A0DEED6Q53643995-9F5BF28F-685D-486D-8156-6457E959813BQ61718329-B8655387-1BFD-4C7F-9626-B2982C745443Q61718338-02BE3EB1-EDF0-4075-BC99-71837705C1E7Q64973187-4B2C7B4D-15FB-4B1E-BDA0-4BC20D34C439Q89767697-FF9D8C3E-B0C6-4B84-A346-29596BCBBD3FQ91861178-0D337B4D-9B8B-4A4B-A48C-1805481EFF45Q92179570-4659F391-B202-4943-A69C-D29579DB730E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Deepa Bhojwani
@ast
Deepa Bhojwani
@en
Deepa Bhojwani
@es
Deepa Bhojwani
@nl
Deepa Bhojwani
@sl
type
label
Deepa Bhojwani
@ast
Deepa Bhojwani
@en
Deepa Bhojwani
@es
Deepa Bhojwani
@nl
Deepa Bhojwani
@sl
prefLabel
Deepa Bhojwani
@ast
Deepa Bhojwani
@en
Deepa Bhojwani
@es
Deepa Bhojwani
@nl
Deepa Bhojwani
@sl
P106
P21
P31
P496
0000-0002-7559-7927
P569
2000-01-01T00:00:00Z